Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Johnson & Johnson

Pinduoduo Inc - ADR

As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-time highs, investors are out bargain hunting.

3 Mega Cap Stock Bargains As Markets Hit All-Time Highs

Novo Nordisk is a growth stock that continues to pleasantly surprise me and investors with the pace of its development of product candidates for the treatment of endocrine diseases. The company's share price reflects optimism about its diabetes franchise, promising results in treating patients with hemophilia A and progress with CagriSema. A more promising experimental drug relative to CagriSema is amycretin, which demonstrated a 13.1% reduction in patient weight after just 12 weeks of treatment.

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet

Bagsværd, Denmark, 18 June 2024 – Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA). The conference will be held in-person and virtually from 21–24 June 2024 in Orlando, US.

Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association

Eli Lilly

Popular weight-loss drugs have boosted Novo Nordisk and Eli Lilly. After huge gains, the drugmakers' stocks now face this risk.

Top Weight-Loss Rivals Share This Risk After Eye-Popping Runs

ASML Hld

AstraZeneca

Wall Street loves coming up with cute little phrases, whether that be “FANG” or the more recent Magnificent 7. However, Thornburg portfolio manager Nicholas Anderson would like investors to be familiar with a new concept: targeting the best Fantastic 5 stocks for potentially blistering upside.

3 Best Stocks to Buy From the Fantastic 5

The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.

Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy

Medtronic

Novo Nordisk and Medtronic are longtime leaders in the healthcare industry. Both are proven innovators with attractive prospects in the years ahead.

Got $200? 2 Healthcare Stocks to Buy and Hold Forever.

Eli Lilly has one obesity drug that's already competing against Wegovy, with more drugs potentially on the way. Novo Nordisk could have a more powerful obesity drug than Wegovy waiting in the wings.

Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug

Amgen

Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) are popular weight-loss drugs that have taken the world by storm. Indeed, the craze is showing no signs of slowing down as more supply of GLP-1 receptor agonists comes online to meet blistering demand.

3 Stocks to Buy as Ozempic Surges in Popularity

SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of DYRK/CLK kinases, has entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes.   This agreement builds upon Biosplice's innovative research, supported by robust external scientific literature, demonstrating the potential of DYRK inhibition to stimulate β-cell proliferation in animal models and human islet cells, thus offering a promising avenue for diabetes treatment.

Biosplice Announces Collaboration with Novo Nordisk in Diabetes

Spotify

Spotify stock, ASML and Novo Nordisk, are in or near buy zones and boast this key signal of stock market leadership.

ASML, Novo Nordisk, Spotify Boast This Sign Of Stock Market Leadership

The U.S. Senate health panel said on Tuesday it would vote later this month on whether to subpoena Novo Nordisk over the high U.S. prices for weight loss drugs Ozempic and Wegovy compared to those offered in other countries.

US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices

LVMH Moet Hennessy Louis Vuitton

SAP SE

Five mega companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks make this list.

Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks

Chevron

Coca-Cola

Microsoft

Target

Taiwan Semiconductor Manufacturing

With so many moving parts in the market, investors shouldn't just focus on explosive growth ideas. Instead, they should turn to the safety of, well, safe stocks to buy.

The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns

Novo Nordisk has two hugely successful assets in Ozempic and Wegovy. A recent trial also found semaglutide effective for treating chronic kidney disease.

Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher

Siemens AG

Historic ECB rate cut bolstered European stocks, which calls for keeping a tab on Siemens (SIEGY), ASML Holding (ASML) and Novo Nordisk (NVO) for solid growth.

ECB Rate Cut Propels European Markets: 3 Must-Watch Stocks

GlaxoSmithKline

Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the economy is performing miserably.

The 3 Most Undervalued Pharma Stocks to Buy in June 2024

Last year, Novo Nordisk, the Danish pharmaceutical giant, witnessed a significant surge in the sales of its diabetes drug Ozempic in China, doubling its revenue to almost $700 million. This remarkable growth accounts for 5 percent of Ozempic's global sales, underscoring China's pivotal role in the drug's international market.

Novo Nordisk's Ozempic sales double to $700 M in China, driven by weight-loss demand

Novo Nordisk is working hard to expand Ozempic's addressable market. The drug is helpful in treating chronic kidney disease, per a new trial.

Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again

European stocks opened higher Thursday, with markets anticipating the ECB will cut borrowing costs for the first time since September 2019.

European stocks open higher as markets anticipate first ECB rate cut since 2019; Novo Nordisk up 3.5%

At least 11 generic versions of Novo Nordisk's popular diabetes drug Ozempic are in the final stages of clinical trials in China, as developers seek to profit from an early patent expiry of the therapy's active ingredient semaglutide in China.

Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic

Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed.

Focus: Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China

AbbVie

Moderna

The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that provide life-changing drugs.

Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential

Novo Nordisk is in a buy zone after a 39% gain year to date. The anti-obesity drug market is expect to grow to $4.4 billion by 2032.

News for Novo Nordisk Stock (NVO)